CD274 and neoplasm: Regarding the role of PD-L1 expression as a predictive biomarker, the KEYNOTE-199 clinical trial showed that the effect of anti-PD-1 (pembrolizumab) monotherapy in metastatic CRPC was independent of PD-L1 expression in the tumor [86,135].